基于癌周免疫炎症因子的肝癌转移预测标签的验证与优化及其对早期肝癌预后预测价值的评价
|
摘要
原发性肝细胞癌在全球癌症病死率中已上升至第3位,在国内居第2位;我国肝癌病人占全球每年因肝癌死亡人数的53%。虽然肝癌研究与治疗已取得很大进展,根治切除术后的十年生存率已提高到30%左右,但即使是小肝癌根治性切除,5年内仍有60-70%的病人出现转移复发,因此探索肝癌转移复发的机制,寻找有效的抑制途径,探索肝癌术后预测因子,准确区分患者,特别是发现早期肝癌的预后因子已成为进一步提高肝癌生存率的关键。基于传统的肿瘤预测因子只能粗略区分不同分期的HCC,对于外科临床实践中常见的早期HCC预测效果较差,本研究拟在原有工作基础上,分析癌周免疫细胞因子表达构成、优化肝癌术后预后预测指标,从基因和蛋白水平进一步验证和优化癌周免疫相关因子的预测标签、探讨其对预后的影响,为向临床应用转化奠定基础。
第一部分基于癌周免疫炎症因子的肝癌转移预测标签的验证与优化及其对早期肝癌预后预测价值的评价:基因表达水平研究
目的:早期肝癌患者预后预测仍然困难,我所前期发现癌旁组织17个免疫炎症相关细胞因子表达谱可以较准确预测肝癌术后早期复发。本研究拟进一步在早期肝癌患者中验证及优化此标签,检验其对早期肝癌术后预后预测的效果。
方法:微流体低密度表达芯片技术(384孔qRT-PCR array)检测HCC癌旁组织的20个免疫细胞因子(包括17个预测标签因子和文献报告的3个复发转移相关因子)mRNA表达水平,应用生物信息学的机器学习方法构建有效的细胞因子预测模型,分析其中BCLC极早期和早期病人细胞因子表达水平与肝癌复发及预后的关系,检验其预测效果。
结果:121例患者中复发和无复发组临床病理特征无显著差别,Cox多因素分析仅有肿瘤大小(P=0.03)对术后复发有显著影响。Cox风险比例回归模型分析20个细胞因子分别对复发的影响,影响大小排序后IL-10(P=0.004),IL-15(P=0.025),IL-2(P=0.013)为前三位,即这三个细胞因子表达情况对术后复发影响较大。IL-2、IL-15等在无复发患者中表达明显升高,患者平均生存期51.2个月,有镜下癌栓组IL-2 mRNA表达量平均值低于无镜下癌栓组(P=0.001)。基于20个细胞因子mRNA表达谱的预测标签在多因素分析中独立于其他临床病理指标,对复发影响风险比OR=5.2(P=2.71E-6);对生存多因素分析风险比为OR=2.5(P=0.012)。进一步筛选发现基于C4.5的决定树模型发现包含IL-2单细胞因子的预测模型可以较准确地预测该组病人复发情况(P=4.28E-5,AUC=0.81,准确率76%),IL-2预测效能高于单包含IL-15的模型。Cox风险回归分析IL-2 mRNA表达水平是肝癌复发的独立影响因子,并且可作为肝癌术后总体生存期预后指标。IL-15对于肝癌术后远期复发具有预测作用,IL-2与IL-15表达显著相关,但是IL-2预测效能高于IL-15。108例病人应用生物信息学方法分为训练组和测试组。ROC曲线确定IL-2或IL-15细胞因子表达临界值,训练组根据阈值分为高风险组和低风险组,Kaplan-Meier分析显示高风险组无瘤生存期显著短于低风险组(P=0.0003),高风险组总生存期也短于低风险组(P=0.016)。测试组分为高复发风险组(21例)和低复发风险组(15例)。高复发风险组无瘤生存期显著低于低分显著(P=0.002),总生存期在两组之间无显著差别(P=0.456)。单独应用IL-2和IL-15细胞因子mRNA作为预测因子的复发预测效能通过ROC曲线评价,曲线下面积AUC=0.73;准确率=70%(P=0.020),与训练组准确性相当。ROC曲线分析IL-2作为独立预测因子准确率可达80%。
结论:20个细胞因子的预测模型预测早期肝癌术后复发的准确率70%,优化后单独IL-2和IL-15细胞因子构建早期肝癌术后预测模型,IL-2mRNA水平预测术后复发率准确率可达80%,癌旁IL-2、IL-15基因表达可以作为TNMI期肝癌术后预后的独立预测因子。
第二部分基于癌周免疫炎症因子的肝癌转移预测标签的验证与优化及其对早期肝癌预后预测价值的评价:蛋白水平研究
目的:前一部分研究从mRNA水平验证了已建立的包含有17个免疫细胞因子肝癌转移预测标签可以准确预测早期肝癌的术后复发,并筛选出IL-2和IL-15基因水平可作为独立预后因子。本研究中,我们从蛋白水平进一步在另一组具有更长随访期的早期病人中验证及优化癌周免疫因子蛋白表达对早期肝癌术后复发的预测作用。
方法:选取187例早期肝癌切除病人癌旁肝组织,采用优化后裂解液总蛋白抽提法,提取癌旁组织总蛋白,ELISA法检测经筛选的第一部分20个免疫炎症细胞因子蛋白表达水平。ROC曲线法分析细胞因子对预后的预测作用,确定细胞因子蛋白水平阈值,根据阈值将病人分为高、低表达组。单因素和多因素Cox回归分析蛋白表达谱与肝癌术后存活、复发的关系。应用生物信息学方法,进一步优化蛋白预测因子。
结果:187例患者临床病理特征单因素分析仅有HBsAg(OR=2.3,95%CI:1.1-4.5)对术后复发有显著影响,多因素分析均无显著意义。Cox风险比例回归模型分析20个细胞因子蛋白水平对复发的影响,按影响大小排序后IL-2(P=0.013)、IL-15(P=0.025),为前两位。在蛋白水平,IL-2(OR=2.9,95%CI:1.7-5.2;P=2.68E-5)和IL-15(OR=1.9,95%CI:1.2-3.2;P=0.005)与肿瘤复发密切相关。生物信息学分析,训练组IL-2(P=0.002)和IL-15对术后无瘤生存期影响显著,高IL-2和(或)IL-15表达水平的HCC病人术后复发率较低,无瘤生存期显著长于低IL-2和IL-15表达组,其中显著性分别为IL-2(P=1.02E-5) IL-15(P=0.004)。癌旁肝组织的IL-2和IL-15蛋白表达相关性较强(P＜0.001)。
结论:IL-2和IL-15蛋白表达是早期肝癌病人术后复发的可靠标签,可以区分不同预后的病人,预测肿瘤术后复发风险。
第三部分肝癌癌周组织浸润淋巴细胞表型及表面标志物表达
目的:癌旁组织免疫炎症相关细胞因子与肿瘤进展及预后关系密切,可以作为预后预测因子,但是癌旁免疫微环境中免疫细胞的状态变化,及其对细胞因子的影响还不清楚,本部分初步分析肝癌患者组织浸润淋巴细胞组织分布与表型及外周血淋巴细胞表型变化与预后的关系。
方法:免疫组织化学染色分析肝癌组织及癌旁组织浸润淋巴细胞表型,检测T细胞或B细胞表面标志物:CD3、CD8、CD4、CD20、CD19、Foxp3,分析浸润淋巴细胞表型及数目和肿瘤临床特征及预后的关系;检测癌旁组织石蜡切片HLA-Ⅰ、HLA-Ⅱ、CD80、CD86表达情况。流式细胞仪检测肝癌病人外周血T细胞CD3、CD8、CD4分析其比例变化。
结果:肝癌肿瘤浸润细胞在癌巢内明显少于癌周组织,癌周淋巴细胞与患者肝炎病史及肝硬化相关,主要分布于间质、汇管区。浸润细胞以CD3+T细胞为主,其中以CD8+T细胞为主;CD4染色在多数病例为阴性,Foxp3仅在个别病例13.8%(15/109)存在。肿瘤浸润淋巴细胞B细胞表面标志CD20、CD19均为阴性。统计分析发现,肿瘤组织内CD8+T细胞浸润数量与预后正相关,而癌周浸润淋巴细胞数目与患者转移及复发无显著关系。癌旁组织HLA-Ⅰ、HLA-Ⅱ、CD80、CD86表达均与肝癌复发及预后无明显关系,但CD86高表达患者有预后好的趋势;HLA-Ⅱ低表达患者预后略差。
结论:肝癌肿瘤浸润细胞在癌巢内明显少于癌周组织(P＜0.01),癌周淋巴细胞与患者肝炎病史及肝硬化相关,肿瘤及癌周浸润细胞以CD3+CD8+T细胞为主;CD4染色在多数病例为阴性,Foxp3仅在个别病例存在。肿瘤组织内CD8+T细胞浸润数量与预后相关,而癌周浸润淋巴细胞表面标志物表达增加,可能影响肝癌术后预后。
全文总结
1.肝细胞癌癌旁组织炎症/免疫微环境细胞因子蛋白和基因表达有其特异性,相关细胞因子与早期肝癌术后预后有关。
2.细胞因子IL-2或IL15与肿瘤血管侵袭负相关,IL-2和IL-15癌旁组织的蛋白和基因水平均可以预测早期肝癌术后复发,IL-2蛋白水平对预后复发预测准确性可达76%,具有潜在的临床应用价值。
3.癌旁组织CD8+T细胞功能性缺失可能造成微环境细胞因子分泌改变,为今后癌周免疫微环境细胞因子来源提供线索。
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and also the third most common cause of cancer-related death, in China, mortality rate had rised second. It has an extremely poor prognosis, attributed to the high frequency of intrahepatic metastatic recurrence. To date, the only effective approaches for patients with HCC are resection or liver transplantation. But even to small HCC, the recurrence rate still was up to 60-70% in 5 years. It is most important to find effective mechanism of metastasis and recurrence aimed to improving the prognosis of HCC. Base on traditional staging system, the patients were hard to predict who had samillar clinical character. How to identify stratify subgroups with different outcome still were great difficulties.
Immunological/ inflammatory mechanisms are important in the surveillance of malignancy and control of tumor progression. In this study, we focused on HCC noncancerous tissue immune microenvironment to further validate and refine a gene or protein signature of cytokine which can predict prognosis of HCC after curative treatment.
Part A
Purpose: Hepatocellular carcinoma (HCC) is a common malignancy, but the prognosis remains poor due to metastasis and recurrence after curative hepatectomy. A 17-cytokine gene expression signature in non-cancerous hepatic tissue from patients with active metastatic HCC was recently found to predict HCC venous metastases. We examined whether a more refined cytokine gene expression profile of noncancerous liver tissue could predict survival of early stage HCC after curative hepatectomy.
Methods: We analyzed a 20-cytokine gene expression profile in noncancerous liver tissue from 121 Chinese patients with TNM stage I～II of HCC using TaqMan~@ low density arrays. We then used supervised hierarchical clustering and log-rank test to analyze the prognostic ability of the cytokine gene profile. Using methods of bioinformatics, build a predictical model, then refined it to explore optimal factor.
Results: Clinicopathologic characteristics Cox analysed hadn't find signifinant effection on recurrence except tumor size (HR = 1.793, 95%CI: 1.056-3.045 ;P = 0.03). Cox analyzed effection on recurrence IL-10, IL-2, IL-15 were ranked in the first three sites. The expression of other Th2 cytokines, including IL-4, IL-6 and IL-8, were decreased in most samples tested compared to normal pool tissuse, but no remarkable relativity was observed with the survival and HCC recurrence. The mRNA-based predictor with logistic regression method, which employed all 20 cytokine gene expression, was excellent recurrence predictor in gene dataset(P= 4.28E-5, the area under the curve=0. 81, accuracy=0.76 on tranining dataset. After refined the model, the expression levels of IL-2 (P = 0. 001) and IL-15 (P=0. 0002) correlated inversely and significantly with intrahepatic microvascular invasion. In the univariate analysis, only the mRNA levels of IL-15 and IL-2, preferable than the traditional clinical characteristics, were significantly associated with HCC recurrence. In the multivariate analysis, the mRNA levels of both IL-2 (HR=2. 0; P = 0.015) and IL-15 (HR=2.0; P = 0.011) were independent predictors of HCC recurrence. Higher mRNA levels of IL-2 (P = 0. 016) or IL-15 (P = 0. 001) were associated with a significantly better relapse-free survival of HCC patients compared to those with lower levels of these cytokines. IL-2 and IL-15 had significant correlation in the noncancerous liver tissues using the Spearman test (Spearman'sρ= . 487; P = 1.88×10~(-7)).
Conclusions: IL-2 or IL-15 of immunity-associated genes signature should allow a sensitive and specific monitoring of survival in HCC.
Part B
Purpose: By analyzing the gene expression profiles of noncancerous hepatic tissue from patients with hepatocellular carcinoma (HCC), we recently identified a 17-cytokine signature that can predict HCC metastasis. In this study, we further validated and refined this signature in protein level for tumor recurrence over a long follow-up period in a much larger and specific cohort of patients with early HCC.
Methods: The protein expression levels of 20 cytokines in the noncancerous hepatic tissues from 187 patients with early stage of HCC were determined using ELISA assays. Univariate and multivariable Cox proportional hazards model and Kaplan-Meier method were used for analyzing the association of their expression profiles with tumor recurrence and survival of patients with HCC. To determinate the threshold values by ROC analyze.
Results: Ranked 20 cytokines by a univariate Cox model for recurrence (Table 1). Of all 20 proteins, IL-2 (P = 0.013), IL-15 (P = 0.049) were the top two significant cytokines for recurrent classification. The protein expression levels of IL-2 (P = 2. 68×10~(-5)) and IL-15 (P = 0. 005) correlated strongly with tumor recurrence, and these correlations had been validated in mRNA levels. The patients with higher level (s) of IL-2 and/or IL-15 had a significantly better relapse-free survival compared with those with lower level (s) of IL-2 (P = 1.02×10~(-5)) and/or IL-15 (P = 0.004). The expression levels of IL-2 and IL-15 correlated with each other. Furthermore, the expression levels of IL-2 and IL-15 correlated inversely and significantly with intrahepatic microvascular invasion.
Conclusion: The IL-2 and IL-15 are useful markers for stratifying the patients with early stage of HCC into subgroups with different probabilities of tumor recurrence, and predicting the patients' prognosis after surgical treatment.
Part C
Purpose: By analyzing the CD molecular expression profiles ofnoncancerous hepatic tissue from patients with hepatocellular carcinoma,we want to identify signature of tumor infiltrating lymphocytes whichmaybe affect the cytokines expression between different outcome HCCpatients. In this study, we identified TIL subtype by some lymphocyticdifferentiation antigen and lymphocyte surface mark.
Methods: The lymphocyte surface marks of tumor infiltrating lymphocytesin the noncancerous hepatic tissues from 146 HCC patients were determinedusing IHC. Univariate and multivariable Cox proportional hazards model and Kaplan-Meier method were used for analyzing the association of their expression levels with tumor recurrence and survival of patients with HCC. Results: The phenotype and cell numbers of tumor-infiltrating lymphocytes (TILs) in noncancerous hepatic tissues of HCC were analyzed via immunohistochemistry of sections from patients undergoing surgery for HCC and via flow cytometry of peripheral blood mononuclear cells. Tumor-infiltrating T-cell function and activation status were assessed via CD80, CD86. More than 86. 4% patients of TILs were quiescent as measured via CD4+ or Foxp3 expression, while more than 90% of CD3(+) T cells expressed CD8+. The proportion of Th cell was quite low compared with the ratio of CD8+ T cell. The proportion in distant nontumor tissue CD19 and CD20 was zero. The proportion T cells subgroup isolated from HCC circulating whole blood didn't show significant shift comepared with normal control, CD4+ T:CD8+ T=1.167±1.04、CD+8 T:CD3+T=0. 288±0.116; CD4+T: CD3+T0.429±0.178. The proportion of CD8+ cells in noncancerous hepatic tissues was higher than in blood (P = 0.000). The expression of HLA-I、HLA-II、CD80、CD86 in noncancerous tissues didn't show significant different between different prognostic group, only showed some tendency for outcome. There had no definite proof about the increasing IL-2 or IL-15 only form activation of Th1, maybe they can be secreted by hepatic cell. Conclusion: TILs in HCC noncancerous hepatic tissues are increased and contain a subpopulation of CD3+CD8+ T cells. Activation functional deletion of tumor-infiltrating T cells could damage tumor-specific immunotherapy.
第一部分基于癌周免疫炎症因子的肝癌转移预测标签的验证与优化及其对早期肝癌预后预测价值的评价:基因表达水平研究
目的:早期肝癌患者预后预测仍然困难,我所前期发现癌旁组织17个免疫炎症相关细胞因子表达谱可以较准确预测肝癌术后早期复发。本研究拟进一步在早期肝癌患者中验证及优化此标签,检验其对早期肝癌术后预后预测的效果。
方法:微流体低密度表达芯片技术(384孔qRT-PCR array)检测HCC癌旁组织的20个免疫细胞因子(包括17个预测标签因子和文献报告的3个复发转移相关因子)mRNA表达水平,应用生物信息学的机器学习方法构建有效的细胞因子预测模型,分析其中BCLC极早期和早期病人细胞因子表达水平与肝癌复发及预后的关系,检验其预测效果。
结果:121例患者中复发和无复发组临床病理特征无显著差别,Cox多因素分析仅有肿瘤大小(P=0.03)对术后复发有显著影响。Cox风险比例回归模型分析20个细胞因子分别对复发的影响,影响大小排序后IL-10(P=0.004),IL-15(P=0.025),IL-2(P=0.013)为前三位,即这三个细胞因子表达情况对术后复发影响较大。IL-2、IL-15等在无复发患者中表达明显升高,患者平均生存期51.2个月,有镜下癌栓组IL-2 mRNA表达量平均值低于无镜下癌栓组(P=0.001)。基于20个细胞因子mRNA表达谱的预测标签在多因素分析中独立于其他临床病理指标,对复发影响风险比OR=5.2(P=2.71E-6);对生存多因素分析风险比为OR=2.5(P=0.012)。进一步筛选发现基于C4.5的决定树模型发现包含IL-2单细胞因子的预测模型可以较准确地预测该组病人复发情况(P=4.28E-5,AUC=0.81,准确率76%),IL-2预测效能高于单包含IL-15的模型。Cox风险回归分析IL-2 mRNA表达水平是肝癌复发的独立影响因子,并且可作为肝癌术后总体生存期预后指标。IL-15对于肝癌术后远期复发具有预测作用,IL-2与IL-15表达显著相关,但是IL-2预测效能高于IL-15。108例病人应用生物信息学方法分为训练组和测试组。ROC曲线确定IL-2或IL-15细胞因子表达临界值,训练组根据阈值分为高风险组和低风险组,Kaplan-Meier分析显示高风险组无瘤生存期显著短于低风险组(P=0.0003),高风险组总生存期也短于低风险组(P=0.016)。测试组分为高复发风险组(21例)和低复发风险组(15例)。高复发风险组无瘤生存期显著低于低分显著(P=0.002),总生存期在两组之间无显著差别(P=0.456)。单独应用IL-2和IL-15细胞因子mRNA作为预测因子的复发预测效能通过ROC曲线评价,曲线下面积AUC=0.73;准确率=70%(P=0.020),与训练组准确性相当。ROC曲线分析IL-2作为独立预测因子准确率可达80%。
结论:20个细胞因子的预测模型预测早期肝癌术后复发的准确率70%,优化后单独IL-2和IL-15细胞因子构建早期肝癌术后预测模型,IL-2mRNA水平预测术后复发率准确率可达80%,癌旁IL-2、IL-15基因表达可以作为TNMI期肝癌术后预后的独立预测因子。
第二部分基于癌周免疫炎症因子的肝癌转移预测标签的验证与优化及其对早期肝癌预后预测价值的评价:蛋白水平研究
目的:前一部分研究从mRNA水平验证了已建立的包含有17个免疫细胞因子肝癌转移预测标签可以准确预测早期肝癌的术后复发,并筛选出IL-2和IL-15基因水平可作为独立预后因子。本研究中,我们从蛋白水平进一步在另一组具有更长随访期的早期病人中验证及优化癌周免疫因子蛋白表达对早期肝癌术后复发的预测作用。
方法:选取187例早期肝癌切除病人癌旁肝组织,采用优化后裂解液总蛋白抽提法,提取癌旁组织总蛋白,ELISA法检测经筛选的第一部分20个免疫炎症细胞因子蛋白表达水平。ROC曲线法分析细胞因子对预后的预测作用,确定细胞因子蛋白水平阈值,根据阈值将病人分为高、低表达组。单因素和多因素Cox回归分析蛋白表达谱与肝癌术后存活、复发的关系。应用生物信息学方法,进一步优化蛋白预测因子。
结果:187例患者临床病理特征单因素分析仅有HBsAg(OR=2.3,95%CI:1.1-4.5)对术后复发有显著影响,多因素分析均无显著意义。Cox风险比例回归模型分析20个细胞因子蛋白水平对复发的影响,按影响大小排序后IL-2(P=0.013)、IL-15(P=0.025),为前两位。在蛋白水平,IL-2(OR=2.9,95%CI:1.7-5.2;P=2.68E-5)和IL-15(OR=1.9,95%CI:1.2-3.2;P=0.005)与肿瘤复发密切相关。生物信息学分析,训练组IL-2(P=0.002)和IL-15对术后无瘤生存期影响显著,高IL-2和(或)IL-15表达水平的HCC病人术后复发率较低,无瘤生存期显著长于低IL-2和IL-15表达组,其中显著性分别为IL-2(P=1.02E-5) IL-15(P=0.004)。癌旁肝组织的IL-2和IL-15蛋白表达相关性较强(P＜0.001)。
结论:IL-2和IL-15蛋白表达是早期肝癌病人术后复发的可靠标签,可以区分不同预后的病人,预测肿瘤术后复发风险。
第三部分肝癌癌周组织浸润淋巴细胞表型及表面标志物表达
目的:癌旁组织免疫炎症相关细胞因子与肿瘤进展及预后关系密切,可以作为预后预测因子,但是癌旁免疫微环境中免疫细胞的状态变化,及其对细胞因子的影响还不清楚,本部分初步分析肝癌患者组织浸润淋巴细胞组织分布与表型及外周血淋巴细胞表型变化与预后的关系。
方法:免疫组织化学染色分析肝癌组织及癌旁组织浸润淋巴细胞表型,检测T细胞或B细胞表面标志物:CD3、CD8、CD4、CD20、CD19、Foxp3,分析浸润淋巴细胞表型及数目和肿瘤临床特征及预后的关系;检测癌旁组织石蜡切片HLA-Ⅰ、HLA-Ⅱ、CD80、CD86表达情况。流式细胞仪检测肝癌病人外周血T细胞CD3、CD8、CD4分析其比例变化。
结果:肝癌肿瘤浸润细胞在癌巢内明显少于癌周组织,癌周淋巴细胞与患者肝炎病史及肝硬化相关,主要分布于间质、汇管区。浸润细胞以CD3+T细胞为主,其中以CD8+T细胞为主;CD4染色在多数病例为阴性,Foxp3仅在个别病例13.8%(15/109)存在。肿瘤浸润淋巴细胞B细胞表面标志CD20、CD19均为阴性。统计分析发现,肿瘤组织内CD8+T细胞浸润数量与预后正相关,而癌周浸润淋巴细胞数目与患者转移及复发无显著关系。癌旁组织HLA-Ⅰ、HLA-Ⅱ、CD80、CD86表达均与肝癌复发及预后无明显关系,但CD86高表达患者有预后好的趋势;HLA-Ⅱ低表达患者预后略差。
结论:肝癌肿瘤浸润细胞在癌巢内明显少于癌周组织(P＜0.01),癌周淋巴细胞与患者肝炎病史及肝硬化相关,肿瘤及癌周浸润细胞以CD3+CD8+T细胞为主;CD4染色在多数病例为阴性,Foxp3仅在个别病例存在。肿瘤组织内CD8+T细胞浸润数量与预后相关,而癌周浸润淋巴细胞表面标志物表达增加,可能影响肝癌术后预后。
全文总结
1.肝细胞癌癌旁组织炎症/免疫微环境细胞因子蛋白和基因表达有其特异性,相关细胞因子与早期肝癌术后预后有关。
2.细胞因子IL-2或IL15与肿瘤血管侵袭负相关,IL-2和IL-15癌旁组织的蛋白和基因水平均可以预测早期肝癌术后复发,IL-2蛋白水平对预后复发预测准确性可达76%,具有潜在的临床应用价值。
3.癌旁组织CD8+T细胞功能性缺失可能造成微环境细胞因子分泌改变,为今后癌周免疫微环境细胞因子来源提供线索。
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and also the third most common cause of cancer-related death, in China, mortality rate had rised second. It has an extremely poor prognosis, attributed to the high frequency of intrahepatic metastatic recurrence. To date, the only effective approaches for patients with HCC are resection or liver transplantation. But even to small HCC, the recurrence rate still was up to 60-70% in 5 years. It is most important to find effective mechanism of metastasis and recurrence aimed to improving the prognosis of HCC. Base on traditional staging system, the patients were hard to predict who had samillar clinical character. How to identify stratify subgroups with different outcome still were great difficulties.
Immunological/ inflammatory mechanisms are important in the surveillance of malignancy and control of tumor progression. In this study, we focused on HCC noncancerous tissue immune microenvironment to further validate and refine a gene or protein signature of cytokine which can predict prognosis of HCC after curative treatment.
Part A
Purpose: Hepatocellular carcinoma (HCC) is a common malignancy, but the prognosis remains poor due to metastasis and recurrence after curative hepatectomy. A 17-cytokine gene expression signature in non-cancerous hepatic tissue from patients with active metastatic HCC was recently found to predict HCC venous metastases. We examined whether a more refined cytokine gene expression profile of noncancerous liver tissue could predict survival of early stage HCC after curative hepatectomy.
Methods: We analyzed a 20-cytokine gene expression profile in noncancerous liver tissue from 121 Chinese patients with TNM stage I～II of HCC using TaqMan~@ low density arrays. We then used supervised hierarchical clustering and log-rank test to analyze the prognostic ability of the cytokine gene profile. Using methods of bioinformatics, build a predictical model, then refined it to explore optimal factor.
Results: Clinicopathologic characteristics Cox analysed hadn't find signifinant effection on recurrence except tumor size (HR = 1.793, 95%CI: 1.056-3.045 ;P = 0.03). Cox analyzed effection on recurrence IL-10, IL-2, IL-15 were ranked in the first three sites. The expression of other Th2 cytokines, including IL-4, IL-6 and IL-8, were decreased in most samples tested compared to normal pool tissuse, but no remarkable relativity was observed with the survival and HCC recurrence. The mRNA-based predictor with logistic regression method, which employed all 20 cytokine gene expression, was excellent recurrence predictor in gene dataset(P= 4.28E-5, the area under the curve=0. 81, accuracy=0.76 on tranining dataset. After refined the model, the expression levels of IL-2 (P = 0. 001) and IL-15 (P=0. 0002) correlated inversely and significantly with intrahepatic microvascular invasion. In the univariate analysis, only the mRNA levels of IL-15 and IL-2, preferable than the traditional clinical characteristics, were significantly associated with HCC recurrence. In the multivariate analysis, the mRNA levels of both IL-2 (HR=2. 0; P = 0.015) and IL-15 (HR=2.0; P = 0.011) were independent predictors of HCC recurrence. Higher mRNA levels of IL-2 (P = 0. 016) or IL-15 (P = 0. 001) were associated with a significantly better relapse-free survival of HCC patients compared to those with lower levels of these cytokines. IL-2 and IL-15 had significant correlation in the noncancerous liver tissues using the Spearman test (Spearman'sρ= . 487; P = 1.88×10~(-7)).
Conclusions: IL-2 or IL-15 of immunity-associated genes signature should allow a sensitive and specific monitoring of survival in HCC.
Part B
Purpose: By analyzing the gene expression profiles of noncancerous hepatic tissue from patients with hepatocellular carcinoma (HCC), we recently identified a 17-cytokine signature that can predict HCC metastasis. In this study, we further validated and refined this signature in protein level for tumor recurrence over a long follow-up period in a much larger and specific cohort of patients with early HCC.
Methods: The protein expression levels of 20 cytokines in the noncancerous hepatic tissues from 187 patients with early stage of HCC were determined using ELISA assays. Univariate and multivariable Cox proportional hazards model and Kaplan-Meier method were used for analyzing the association of their expression profiles with tumor recurrence and survival of patients with HCC. To determinate the threshold values by ROC analyze.
Results: Ranked 20 cytokines by a univariate Cox model for recurrence (Table 1). Of all 20 proteins, IL-2 (P = 0.013), IL-15 (P = 0.049) were the top two significant cytokines for recurrent classification. The protein expression levels of IL-2 (P = 2. 68×10~(-5)) and IL-15 (P = 0. 005) correlated strongly with tumor recurrence, and these correlations had been validated in mRNA levels. The patients with higher level (s) of IL-2 and/or IL-15 had a significantly better relapse-free survival compared with those with lower level (s) of IL-2 (P = 1.02×10~(-5)) and/or IL-15 (P = 0.004). The expression levels of IL-2 and IL-15 correlated with each other. Furthermore, the expression levels of IL-2 and IL-15 correlated inversely and significantly with intrahepatic microvascular invasion.
Conclusion: The IL-2 and IL-15 are useful markers for stratifying the patients with early stage of HCC into subgroups with different probabilities of tumor recurrence, and predicting the patients' prognosis after surgical treatment.
Part C
Purpose: By analyzing the CD molecular expression profiles ofnoncancerous hepatic tissue from patients with hepatocellular carcinoma,we want to identify signature of tumor infiltrating lymphocytes whichmaybe affect the cytokines expression between different outcome HCCpatients. In this study, we identified TIL subtype by some lymphocyticdifferentiation antigen and lymphocyte surface mark.
Methods: The lymphocyte surface marks of tumor infiltrating lymphocytesin the noncancerous hepatic tissues from 146 HCC patients were determinedusing IHC. Univariate and multivariable Cox proportional hazards model and Kaplan-Meier method were used for analyzing the association of their expression levels with tumor recurrence and survival of patients with HCC. Results: The phenotype and cell numbers of tumor-infiltrating lymphocytes (TILs) in noncancerous hepatic tissues of HCC were analyzed via immunohistochemistry of sections from patients undergoing surgery for HCC and via flow cytometry of peripheral blood mononuclear cells. Tumor-infiltrating T-cell function and activation status were assessed via CD80, CD86. More than 86. 4% patients of TILs were quiescent as measured via CD4+ or Foxp3 expression, while more than 90% of CD3(+) T cells expressed CD8+. The proportion of Th cell was quite low compared with the ratio of CD8+ T cell. The proportion in distant nontumor tissue CD19 and CD20 was zero. The proportion T cells subgroup isolated from HCC circulating whole blood didn't show significant shift comepared with normal control, CD4+ T:CD8+ T=1.167±1.04、CD+8 T:CD3+T=0. 288±0.116; CD4+T: CD3+T0.429±0.178. The proportion of CD8+ cells in noncancerous hepatic tissues was higher than in blood (P = 0.000). The expression of HLA-I、HLA-II、CD80、CD86 in noncancerous tissues didn't show significant different between different prognostic group, only showed some tendency for outcome. There had no definite proof about the increasing IL-2 or IL-15 only form activation of Th1, maybe they can be secreted by hepatic cell. Conclusion: TILs in HCC noncancerous hepatic tissues are increased and contain a subpopulation of CD3+CD8+ T cells. Activation functional deletion of tumor-infiltrating T cells could damage tumor-specific immunotherapy.
引文
[1]. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol 2009;27(9):1485-91.
[2].E1-Serag HB. Hepatocellular carcinoma: Recent trends in the United States.Gastroenterology 2004;127: S27-S34.
[3]. Salnikov AV, Kusumawidjaja G, Rausch V, et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 2009;275: 185-93.
[4].Wong IHN, Lau WY, Leung T, Yeo W, Johnson PJ. Hematogenous Dissemination of Hepatocytes and Tumor Cells after Surgical Resection of Hepatocellular Carcinoma: A Quantitative Analysis. Clin Cancer Res 1999;5: 4021-7.
[5].Wang J, Li Q, Sun Y, et al: Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surgical Oncology 2009;18:25-30,
[6].Yoshioka S, Takemasa I, Nagano H, et al: Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer 2009;45:881-9,
[7].Lu WP, Dong JH, Huang ZQ, Guo DY, Liu YS, Shi SA. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. Journal of Gastroenterology and Hepatology 2008;23: 1874-8.
[8].Aravalli RN, Steer CJ, Cressman ENK: Molecular Mechanisms of Hepatocellular Carcinoma. Hepatology 2008;48:2047-2063
[9].Seike M, Yanaihara N, Bowman ED, et al: Use of a Cytokine Gene Expression Signature in Lung Adenocarcinoma and the Surrounding Tissue as a Prognostic Classifier. J. Natl. Cancer Inst. 2007;99:1257-1269
[10].Naoya Kato et al: Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C.Hepatology 2005;42:846-853
[11].Alexandra Nieters: Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 2005; 103:740-748
[12].Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP.Prognostic molecular markers in hepatocellular carcinoma: A systematic review.European Journal of Cancer 2007;43: 979-92.
[13].Budhu A, Wang XW.The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006;80: 1197-213.
[14].Budhu A, Forgues M, Ye Q-H, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111,
[15].Seike M, Yanaihara N, Bowman ED,et al.Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.J Natl Cancer Inst. 2007;99(16):1257-69.
[16].Hoshida Y, Villanueva A, Kobayashi M, et al: Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine 2008;359:1995-2004
[17].Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle.Journal of Hepatology 2008;48: 380-1.
[18].Li Bai GP, M. A. O, Chuan Ping ,C. A. O. Effects of inflammatory cytokines on the recurrence of liver cancer after an apparently curative operation.Journal of Digestive Diseases 2007;8:154-9.
[19].Trevisani F, Cantarini MC, Wands JR,ET AL. Recent advances in the natural history of hepatocellular carcinoma.Carcinogenesis.2008 Jul;29(7):1299-305
[1]. Peter Jepsen HV, Robert E. Tarone,et al : Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: Recent trends.International Journal of Cancer. 2007;121:1624-1626.
[2]. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol. 2009:27(9):1485-91.
[3].El-Serag HB. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 2004;127: S27-S34.
[4]. Cunningham SC, Tsai S, Marques HP, et al. Management of Early Hepatocellular Carcinoma in Patients with Well-Compensated Cirrhosis.Ann Surg Oncol. 2009; 7. [Epub ahead of print].
[5].Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26(16):2707-16.
[6].Cunningham SC, Tsai S, Marques HP, et al. Management of Early Hepatocellular Carcinoma in Patients with Well-Compensated Cirrhosis.Ann Surg Oncol. 2009 Mar 7. [Epub ahead of print]
[7].Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9(4):416-23.
[8].Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases,recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell.2006;10(2):99-lll
[9].Hoshida Y, Villanueva A, Kobayashi M, et al: Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine , 2008;359:1995-2004
[10]. Kobayashi N, Hiraoka N, Yamagami W, et al: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13(3):902-11.
[11].Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586-93.
[12]. Fu J, Xu D, Liu Z, Shi M, Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132(7):2328-39.
[13].Cao DY, Yang JY, Dou KF, alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4-and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Hum Immunol. 2007;68(5):334-41.
[14].Kinter AL, Godbout EJ, McNally JP, et al.The common gamma-chain cytokines IL-2, IL-7, IL—15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181(10):6738-46.
[15]. Benson DM Jr, Yu J, Becknell B, et al. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 2009;113(12): 2706-14.
[16].Zuo J, Stohlman SA, Parra GI, et al. IL-15 independent maintenance of virus-specific CD8(+) T cells in the CNS during chronic infection. J Neuroimmunol. 2009;207(1-2):32-8.
[17]. Morris SC, Heidorn SM, Herbert DR, et al. Endogenously produced IL-4 nonredundantly stimulates CD8+ T cell proliferation. J Immunol.2009;182(3):1429-38.
[18].Hecker A, Kaufmann A, Hecker M, Expression of interleukin-21,interleukin-21 receptor alpha and related type I cytokines by intravascular graft leukocytes during acute renal allograft rejection.Immunobiology. 2009;214(1):41-9.
[19]. Rosenthal R, Groeper C, Bracci L, et al. Differential Responsiveness to IL-2, IL-7, and IL-15 Common Receptor gamma Chain Cytokines by Antigen-specific Peripheral Blood Naive or Memory Cytotoxic CD8+ T Cells From Healthy Donors and Melanoma Patients. J Immunother. 2009 Feb 24.[Epub ahead of print]
[20].Ikeguchi M, Hirooka Y. Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie.2005; 28(5): 255-9.
[21]. Terasaki F, Ukimura A, Tsukada B, et al. Enhanced expression of type 1 helper T-cell cytokines in the myocardium of active cardiac sarcoidosis. Circ J.2008,72(8):1303-7
[22].C.Berasain JC,M.J.Perugorria,M.U.Latasa,J.Prieto,M.A.Avila,:Inflammation and Liver Cancer.Annals of the New York Academy of Sciences 2009;1155:206-221
[23].Budhu A,Wang XW.The role of cytokines in hepatocellular carcinoma.J Leukoc Biol.2006;80(6):1197-213.
[24].Seike M,Yanaihara N,Bowman ED,et al.Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.J Natl Cancer Inst.2007;99(16):1257-69.
[25].Wong VW,Yu J,Cheng AS,et al.High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.Int J Cancer.2009 Jan 21.[Epub ahead of print]
[26].Gao LB,Rao L,Wang YY,et al.The association of interleukin-16polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer.Carcinogenesis.2009;30(2):295-9.
[27].Porta C,De Amici M,Quaglini S,et al.Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.Ann Oncol.2008;19(2):353-8.
[28].Sun JJ,Zhou XD,Zhou G,et al.Expression of intercellular adhesive molecule-1 in liver cancer tissues andliver cancer metastasis.World J Gastroenterol.1998;4(3):202-205.
[29].钦伦秀、孙惠川、汤钊猷。原发性肝癌研究进展--2006沪港国际肝病大会纪要。中华外科杂志。2006,44(15)期,1070-1074
[30].汤钊猷。从肝癌看癌症临床研究。肿瘤。2009,29(1):1-4。
[31].Farinati F,Sergio A,Baldan A,et al.Early and very early hepatocellular carcinoma:when and how much do staging and choice of treatment really matter? A multi-center study.BMC Cancer.2009;9:33
[32].Grieco A,Pompili M,Caminiti G,et al.Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:comparison of Okuda,CLIP,and BCLC staging systems in a single Italian centre.Gut.2005;54(3):411-8.
[33].Pons F,Varela M,Llovet JM.Staging systems in hepatocellular carcinoma.HPB(Oxford).2005;7(1):35-41.
[34].Toyama T,Hiramatsu N,Yakushijin T,et al.A new prognostic system for hepatocellular carcinoma including recurrent cases:a study of 861 patients in a single institution. J Clin Gastroenterol.2008;42(3): 317-22.
[35]. Chen CH, Hu FC, Huang GT, Lee PH, et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method - Analysis of 2010 Taiwanese patients. Eur J Cancer. 2009 Jan 19.[Epub ahead of print].
[36]. Okamoto M, Utsunomiya T, Wakiyama S, et al. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol. 2006;13(7):947-54.
[37]. Yoshioka S, Takemasa I, Nagano H, et al. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer. 2009;45(5):881-9.
[38]. Aravalli RN, Steer CJ, et al. Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48(6):2047-63
[39]. Woo HG, Park ES,Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14(7):2056-64.
[40]. Blum DL, Koyama T, M'koma AE, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008;14(23):7790-7.
[41]. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008 99(10) :2037-44.
[42]. Chang YT, Chang MC, Wei SC,et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas.2008;37(2): 145-50.
[43]. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-4.
[44]. Conrad R, Remberger M, Cederlund K,et al. Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer. Biol Blood Marrow Transplant.2006;12(3): 346-54.
[45].Moeller M, Kershaw MH, Cameron R, et al. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res. 2007:67(23):11428-37.
[46]. Song le H, Binh VQ, Duy DN, et al. Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis Bvirus.J Clin Virol.2003;28(1):93-103.
[47]. King JW, Thomas S, Corsi F, et al. IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.Clin Cancer Res. 2009;15(4):1145-54
[48]. Salcedo R, Hixon JA, Stauffer JK, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization,tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol.2009:182(7):4328-38.
[49]. Tang F, Zhao LT, Jiang Y, et al. Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice. Cell Mol Immunol. 2008;5(3):189-96
[50].Daudt L, Maccario R, Locatelli F, et al. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated,antileukemia human cytotoxic T lymphocyte lines. J Immunother.2008;31(4):385-93.
[51].Komita H, Homma S, Saotome H, et al. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol. 2006; 45 (5):662-72.
[52]. Chen CH, Lee HS, Huang GT, Yang PM, et al.Phenotypic analysis of tumor-infiltrating lymphocytes in hepatocellular carcinoma.Hepatogastroenterology. 2007;54(77):1529-33.
[53]. Koido S, Homma S, Hara E, et al. In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J Transl Med. 2008;6:51.
[54]. Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44 Suppl 19:102-7.
[55]. Wu HC, Wang Q, Yang HI, et al. Aflatoxin Bl exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009;18(3):846-53
[56].Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009:13. [Epub ahead of print]
[57]. Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192-9.
[58].Unitt E, Rushbrook SM, Marshall A, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005;41(4):722-30.
[59]. Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13(3):902-11.
[60]. Sasaki A, Tanaka F, Mimori K, et al. Prognostic value of tumor-infiltrating F0XP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol. 2008;34(2):173-9.
[61].Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006;45(2):246-53.
[62].Cai L, Zhang Z, Zhou L, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008;129(3):428-37.
[63].Maki A, Matsuda M, Asakawa M, et al. Decreased CD3 zeta molecules of T lymphocytes from patients with hepatocellular carcinoma associated with hepatitis C virus. Hepatol Res. 2003;27(4):272-278.
[64]. Weidmann E, Whiteside TL, Giorda R, et al.The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res. 1992;52(21):5913-20.
[65]. Zhang J, Dong B, Liang P,et al. Significance of changes in local immunity in patients with hepatocellular carcinoma after percutaneous microwave coagulation therapy. Chin Med J (Engl). 2002;115(9):1367-71.
[66].Homma S, Komita H, Sagawa Y, et al. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against HLA class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology. 2005;115(4):451-61.
[67]. Koido S, Homma S, Hara E, et al. In vitro generation of cytotoxic andregulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J Transl Med. 2008;6:51.
[68]. Wang XH, QinY, Hu MH, et al. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma(HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 2005; 54(10):971-80.
[69].Li ZS, Yang XW, Chen Z, et al. In vivo tumor co-transfection with superantigen and CD80 induces systemic immunity without tolerance and prolongs survival in mice with hepatocellular carcinoma. Cancer Biol Ther.2004:3(7): 660-6.
[70]. Tatsumi T, Takehara T, Katayama K, et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology. 1997;25(5):1108-14.
1. El-Serag HB: Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 127:S27-S34, 2004
2. Kim WR, Gores GJ, Benson JT, et al: Mortality and Hospital Utilization for Hepatocellular Carcinoma in the United States.Gastroenterology 129:486-493, 2005
3. Jepsen P, Vilstrup H, Tarone RE, et al: Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: Recent trends.International Journal of Cancer 121:1624-1626, 2007
4. Davila JA, Weston A, Smalley W, et al: Utilization of screening for hepatocellular carcinoma in the United States. [see comment]. Journal of Clinical Gastroenterology 41:777-82, 2007
5. Kato N, Ji G, Wang Y, Baba M, et al: Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 42:846-853, 2005
6. Ding S-J, Li Y, Tan Y-X, et al: From Proteomic Analysis to Clinical Significance: Overexpression of Cytokeratin 19 Correlates with Hepatocellular Carcinoma Metastasis. Mol Cell Proteomics 3:73-81, 2004
7. Yokoo H, Kondo T, Okano T, et al: Protein expression associated with early intrahepatic recurrence of hepatocellular carcinoma after curative surgery. Cancer Science 98:665-673, 2007
8. Parfitt JR, Marotta P, Alghamdi M, et al: Recurrent hepatocellular carcinoma after transplantation: Use of a pathological score on explanted livers to predict recurrence. Liver Transplantation 13:543-551, 2007
9. Huo TI, Huang YH, Lin HC, et al: Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. American Journal of Gastroenterology 101:975-982,2006
10. Nanashima A, Sumida Y, Abo T, et al: Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. Journal of Gastroenterology 41:250-256, 2006
11. Toyoda H, Kumada T, Osaki Y, et al: Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clinical Gastroenterology & Hepatology 4:1528-1536, 2006
12. Ren Y, Poon RT-P, Tsui H-T, et al: Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and Prognosis. Clin Cancer Res 9:5996-6001,2003
13. Georgiades CS, Liapi E, Frangakis C, et al: Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. Journal of Vascular & Interventional Radiology 17:1619-24, 2006
14. Minagawa M, Ikai I, Matsuyama Y, et al: Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13, 772 patients in Japan. Annals of Surgery 245:909-22, 2007
15. Kee KM, Wang JH, Lee CM, et al: Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5, 613 cases from a medical center in southern Taiwan. International Journal of Cancer 120:2650-5, 2007
16. Ramacciato G, Mercantini P, Cautero N, et al: Prognostic evaluation of the new American Joint Committee on Cancer/International Union Against Cancer staging system for hepatocellular carcinoma: analysis of 112 cirrhotic patients resected for hepatocellular carcinoma. [see comment]. Annals of Surgical Oncology 12:289-97, 2005
17. Takanishi DM, Jr., Severino R, Wong LL: The Cancer of the Liver Italian Program (CLIP) score: validation of a new prognostic system for hepatocellular carcinoma. Hawaii Medical Journal 66:209-12, 2007
18. Ho M-C, Lin J-J, Chen C-N, et al: A Gene Expression Profile for Vascular Invasion can Predict the Recurrence After Resection of Hepatocellular Carcinoma: a Microarray Approach. Annals of Surgical Oncology 13:1474-1484, 2006
19. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma:Comparison of 7 staging systems in an American cohort.Hepatology 41:707-715, 2005
20. Vanderkerken K, Bouwens L, Van Rooi jen N, et al: The role of Kupf fer cells in the differentiation process of hepatic natural killer cells.Hepatology 22:283-90, 1995
21. McCullough KD, Coleman WB, Smith GJ, et al: Age-dependent induction of hepatic tumor regression by the tissue microenvironment after transplantation of neoplastically transformed rat liver epithelial cells into the liver. Cancer Research 57:1807-13, 1997
22. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47(3): 897-907, 2008
23. Unitt E, Rushbrook SM, Marshall A, et al: Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells, [see comment]. Hepatology 41:722-30, 2005
24. Kanmura S, Uto H, Kusumoto K, et al: Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology 45:948-956, 2007
25. Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. [see comment]. Journal of Clinical Oncology 25:2586-93, 2007
26. Kobayashi N, Hiraoka N, Yamagami W, et al: F0XP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clinical Cancer Research 13:902-11, 2007
27. Cai XY, Gao Q, Qiu SJ, et al: Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. Journal of Cancer Research & Clinical Oncology 132:293-301, 2006
28. Cai XY, Qiu SJ, Wu ZQ, et al: [Relationship between dendritic cells and memory T lymphocytes in tumor site and prognosis of hepatocellular carcinoma]. Chung-Hua i Hsueh TsaChih [Chinese Medical Journal] 85:671-5,2005
29. Hira E, Ono T, Dhar DK, et al: Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103:588-598, 2005
30. Wang L, Wu WZ, Sun HC, et al: Mechanism of Interferon Alpha on Inhibition of Metastasis and Angiogenesis of Hepatocellular Carcinoma After Curative Resection in Nude Mice. Journal of Gastrointestinal Surgery 7:587-594, 2003
31. Mann CD, Neal CP, Garcea G, et al: Prognostic molecular markers in hepatocellular carcinoma: A systematic review. European Journal of Cancer 43:979-992, 2007
32. Poon TCW, Wong N, Lai PBS, et al: A Tumor Progression Model for Hepatocellular Carcinoma: Bioinformatic Analysis of Genomic Data. Gastroenterology 131:1262-1270, 2006
33. Qin LX, Tang ZY, Sham JST, et al: The Association of Chromosome 8p Deletion and Tumor Metastasis in Human Hepatocellular Carcinoma. Cancer Res 59:5662-5665, 1999
34. Kusano N, Okita K, Shirahashi H, : Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer 94:746-751, 2002
35. Chan KL, Lee JM, Guan XY: High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer 94:3179-3185, 2002
36. Li SP, Wang HY, Li JQ, et al: Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. Journal of Hepatology 34:840-849, 2001
37. Pang JZ, Qin LX, Ren N, et al: Loss of Heterozygosity at D8S298 Is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma. Clin Cancer Res 13:7363-7369, 2007
38. Wu L, Xu X, Shen J, et al: MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation. Journal of Surgical Oncology 96:62-68, 2007
39. Chen GG, Ho RLK, Wong J, et al: Single nucleotide polymorphism in the promoter region of human alpha-fetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC). European Journal ofSurgical Oncology (EJSO) 33:882-886, 2007
40. Dharel N, Kato N, Muroyama R, et al: MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C. Clin Cancer Res 12:4867-4871, 2006
41. Luk JM, Lam CT, Siu AF, et al: Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. PROTEOMICS 6:1049-1057, 2006
42. Ren N, Qin LX, Tu H, et al: The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 132:399-407, 2006
43. Wong IHN, Lau WY, Leung T, et al: Hematogenous Dissemination of Hepatocytes and Tumor Cells after Surgical Resection of Hepatocellular Carcinoma: A Quantitative Analysis. Clin Cancer Res 5:4021-4027, 1999
44. Sun HC, Zhang W, Qin LX, et al: Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. Journal of Hepatology 47:684-690, 2007
45. Chau GY WC, et al: Serum Interleukin-10 But Not Interleukin-6 Is Related to Clinical Outcome in Patients With Resectable Hepatocellular Carcinoma. Annals of surgery 231:552-558. , 2000
46. Ikeguchi M HY: Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie 28:255-9. Epub 2005 Apr 29., 2005
47. Okabe H, Satoh S, Kato T, et al: Genome-wide Analysis of Gene Expression in Human Hepatocellular Carcinomas Using cDNA Microarray:Identification of Genes Involved in Viral Carcinogenesis and Tumor Progression. Cancer Res 61:2129-2137, 2001
48. Cheung ST, Chen X, Guan XY, et al: Identify Metastasis-associated Genes in Hepatocellular Carcinoma through Clonality Delineation for Multinodular Tumor. Cancer Res 62:4711-4721, 2002
49. Iizuka N, Oka M, Yamada Okabe H, et al: Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. The Lancet 361:923-929, 2003
50. Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416-423,2003
51. Mas VR, Maluf DG, Stravitz R, et al. : Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: Genes involved in tumor progression. Liver Transplantation 10:607-620, 2004
52. Katoh H, Shibata T, Kokubu A, et al: Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: Identification of genetic indicators to predict patient outcome. Journal of Hepatology 43:863-874, 2005
53. Okamoto M, Utsunomiya T, Wakiyama S, et al: Specific Gene-Expression Profiles of Noncancerous Liver Tissue Predict the Risk for Multicentric Occurrence of Hepatocellular Carcinoma in Hepatitis C Virus - Positive Patients. Annals of Surgical Oncology 13:947-954, 2006
54. Valeria R Mas DGM, Kellie J Archer, Kenneth Yanek, Bridgette Williams, Robert A Fisher: Differentially Expressed Genes between Early and Advanced Hepatocellular Carcinoma (HCC) as a Potential Tool for Selecting Liver Transplant Recipients. Mol Med. Apr-Jun; 12: 97-104. ,2006
55. Lee JS, Heo J, Libbrecht L, et al: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12:410-416, 2006
56. Wang SM, Ooi LLPJ, Hui KM: Identification and Validation of a Novel Gene Signature Associated with the Recurrence of Human Hepatocellular Carcinoma. Clin Cancer Res 13:6275-6283, 2007
57. Hideaki Somura NI, Takao Tamesa, Kazuhiko Sakamoto, Takashi Hamaguchi, Ryouichi Tsunedomi, Hisafumi Yamada-Okabe, Mikiko Sawamura,Masaya Eramoto, Takanobu Miyamoto, Yoshihiko Hamamoto, Masaaki Oka: A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy. Oncology Reports 19:489-95, 2008
58. Melle C, Ernst G, Scheibner O, et al: Identification of Specific Protein Markers in Microdissected Hepatocellular Carcinoma. J. Proteome Res. 6:306-315, 2007
59. Luk JM, Lam BY, Lee NPY, et al: Artificial neural networks and decision tree model analysis of liver cancer proteomes. Biochemical and Biophysical Research Communications 361:68-73, 2007
60. Yi X, Luk JM, Lee NP, et al: Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence. Mol Cell Proteomics 7:315-325, 2008
61. Lim SO PS, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, Yoo BC, Jung GH, Park CK. : Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol 11:2072-2079,2005
62. Poon TCW, Yip TT, Chan ATC, et al: Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its Subtypes. Clin Chem 49:752-760, 2003
[2].E1-Serag HB. Hepatocellular carcinoma: Recent trends in the United States.Gastroenterology 2004;127: S27-S34.
[3]. Salnikov AV, Kusumawidjaja G, Rausch V, et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 2009;275: 185-93.
[4].Wong IHN, Lau WY, Leung T, Yeo W, Johnson PJ. Hematogenous Dissemination of Hepatocytes and Tumor Cells after Surgical Resection of Hepatocellular Carcinoma: A Quantitative Analysis. Clin Cancer Res 1999;5: 4021-7.
[5].Wang J, Li Q, Sun Y, et al: Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surgical Oncology 2009;18:25-30,
[6].Yoshioka S, Takemasa I, Nagano H, et al: Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer 2009;45:881-9,
[7].Lu WP, Dong JH, Huang ZQ, Guo DY, Liu YS, Shi SA. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. Journal of Gastroenterology and Hepatology 2008;23: 1874-8.
[8].Aravalli RN, Steer CJ, Cressman ENK: Molecular Mechanisms of Hepatocellular Carcinoma. Hepatology 2008;48:2047-2063
[9].Seike M, Yanaihara N, Bowman ED, et al: Use of a Cytokine Gene Expression Signature in Lung Adenocarcinoma and the Surrounding Tissue as a Prognostic Classifier. J. Natl. Cancer Inst. 2007;99:1257-1269
[10].Naoya Kato et al: Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C.Hepatology 2005;42:846-853
[11].Alexandra Nieters: Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 2005; 103:740-748
[12].Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP.Prognostic molecular markers in hepatocellular carcinoma: A systematic review.European Journal of Cancer 2007;43: 979-92.
[13].Budhu A, Wang XW.The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006;80: 1197-213.
[14].Budhu A, Forgues M, Ye Q-H, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111,
[15].Seike M, Yanaihara N, Bowman ED,et al.Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.J Natl Cancer Inst. 2007;99(16):1257-69.
[16].Hoshida Y, Villanueva A, Kobayashi M, et al: Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine 2008;359:1995-2004
[17].Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle.Journal of Hepatology 2008;48: 380-1.
[18].Li Bai GP, M. A. O, Chuan Ping ,C. A. O. Effects of inflammatory cytokines on the recurrence of liver cancer after an apparently curative operation.Journal of Digestive Diseases 2007;8:154-9.
[19].Trevisani F, Cantarini MC, Wands JR,ET AL. Recent advances in the natural history of hepatocellular carcinoma.Carcinogenesis.2008 Jul;29(7):1299-305
[1]. Peter Jepsen HV, Robert E. Tarone,et al : Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: Recent trends.International Journal of Cancer. 2007;121:1624-1626.
[2]. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol. 2009:27(9):1485-91.
[3].El-Serag HB. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 2004;127: S27-S34.
[4]. Cunningham SC, Tsai S, Marques HP, et al. Management of Early Hepatocellular Carcinoma in Patients with Well-Compensated Cirrhosis.Ann Surg Oncol. 2009; 7. [Epub ahead of print].
[5].Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26(16):2707-16.
[6].Cunningham SC, Tsai S, Marques HP, et al. Management of Early Hepatocellular Carcinoma in Patients with Well-Compensated Cirrhosis.Ann Surg Oncol. 2009 Mar 7. [Epub ahead of print]
[7].Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9(4):416-23.
[8].Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases,recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell.2006;10(2):99-lll
[9].Hoshida Y, Villanueva A, Kobayashi M, et al: Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine , 2008;359:1995-2004
[10]. Kobayashi N, Hiraoka N, Yamagami W, et al: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13(3):902-11.
[11].Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586-93.
[12]. Fu J, Xu D, Liu Z, Shi M, Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132(7):2328-39.
[13].Cao DY, Yang JY, Dou KF, alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4-and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Hum Immunol. 2007;68(5):334-41.
[14].Kinter AL, Godbout EJ, McNally JP, et al.The common gamma-chain cytokines IL-2, IL-7, IL—15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181(10):6738-46.
[15]. Benson DM Jr, Yu J, Becknell B, et al. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 2009;113(12): 2706-14.
[16].Zuo J, Stohlman SA, Parra GI, et al. IL-15 independent maintenance of virus-specific CD8(+) T cells in the CNS during chronic infection. J Neuroimmunol. 2009;207(1-2):32-8.
[17]. Morris SC, Heidorn SM, Herbert DR, et al. Endogenously produced IL-4 nonredundantly stimulates CD8+ T cell proliferation. J Immunol.2009;182(3):1429-38.
[18].Hecker A, Kaufmann A, Hecker M, Expression of interleukin-21,interleukin-21 receptor alpha and related type I cytokines by intravascular graft leukocytes during acute renal allograft rejection.Immunobiology. 2009;214(1):41-9.
[19]. Rosenthal R, Groeper C, Bracci L, et al. Differential Responsiveness to IL-2, IL-7, and IL-15 Common Receptor gamma Chain Cytokines by Antigen-specific Peripheral Blood Naive or Memory Cytotoxic CD8+ T Cells From Healthy Donors and Melanoma Patients. J Immunother. 2009 Feb 24.[Epub ahead of print]
[20].Ikeguchi M, Hirooka Y. Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie.2005; 28(5): 255-9.
[21]. Terasaki F, Ukimura A, Tsukada B, et al. Enhanced expression of type 1 helper T-cell cytokines in the myocardium of active cardiac sarcoidosis. Circ J.2008,72(8):1303-7
[22].C.Berasain JC,M.J.Perugorria,M.U.Latasa,J.Prieto,M.A.Avila,:Inflammation and Liver Cancer.Annals of the New York Academy of Sciences 2009;1155:206-221
[23].Budhu A,Wang XW.The role of cytokines in hepatocellular carcinoma.J Leukoc Biol.2006;80(6):1197-213.
[24].Seike M,Yanaihara N,Bowman ED,et al.Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.J Natl Cancer Inst.2007;99(16):1257-69.
[25].Wong VW,Yu J,Cheng AS,et al.High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.Int J Cancer.2009 Jan 21.[Epub ahead of print]
[26].Gao LB,Rao L,Wang YY,et al.The association of interleukin-16polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer.Carcinogenesis.2009;30(2):295-9.
[27].Porta C,De Amici M,Quaglini S,et al.Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.Ann Oncol.2008;19(2):353-8.
[28].Sun JJ,Zhou XD,Zhou G,et al.Expression of intercellular adhesive molecule-1 in liver cancer tissues andliver cancer metastasis.World J Gastroenterol.1998;4(3):202-205.
[29].钦伦秀、孙惠川、汤钊猷。原发性肝癌研究进展--2006沪港国际肝病大会纪要。中华外科杂志。2006,44(15)期,1070-1074
[30].汤钊猷。从肝癌看癌症临床研究。肿瘤。2009,29(1):1-4。
[31].Farinati F,Sergio A,Baldan A,et al.Early and very early hepatocellular carcinoma:when and how much do staging and choice of treatment really matter? A multi-center study.BMC Cancer.2009;9:33
[32].Grieco A,Pompili M,Caminiti G,et al.Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:comparison of Okuda,CLIP,and BCLC staging systems in a single Italian centre.Gut.2005;54(3):411-8.
[33].Pons F,Varela M,Llovet JM.Staging systems in hepatocellular carcinoma.HPB(Oxford).2005;7(1):35-41.
[34].Toyama T,Hiramatsu N,Yakushijin T,et al.A new prognostic system for hepatocellular carcinoma including recurrent cases:a study of 861 patients in a single institution. J Clin Gastroenterol.2008;42(3): 317-22.
[35]. Chen CH, Hu FC, Huang GT, Lee PH, et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method - Analysis of 2010 Taiwanese patients. Eur J Cancer. 2009 Jan 19.[Epub ahead of print].
[36]. Okamoto M, Utsunomiya T, Wakiyama S, et al. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol. 2006;13(7):947-54.
[37]. Yoshioka S, Takemasa I, Nagano H, et al. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer. 2009;45(5):881-9.
[38]. Aravalli RN, Steer CJ, et al. Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48(6):2047-63
[39]. Woo HG, Park ES,Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14(7):2056-64.
[40]. Blum DL, Koyama T, M'koma AE, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008;14(23):7790-7.
[41]. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008 99(10) :2037-44.
[42]. Chang YT, Chang MC, Wei SC,et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas.2008;37(2): 145-50.
[43]. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-4.
[44]. Conrad R, Remberger M, Cederlund K,et al. Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer. Biol Blood Marrow Transplant.2006;12(3): 346-54.
[45].Moeller M, Kershaw MH, Cameron R, et al. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res. 2007:67(23):11428-37.
[46]. Song le H, Binh VQ, Duy DN, et al. Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis Bvirus.J Clin Virol.2003;28(1):93-103.
[47]. King JW, Thomas S, Corsi F, et al. IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.Clin Cancer Res. 2009;15(4):1145-54
[48]. Salcedo R, Hixon JA, Stauffer JK, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization,tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol.2009:182(7):4328-38.
[49]. Tang F, Zhao LT, Jiang Y, et al. Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice. Cell Mol Immunol. 2008;5(3):189-96
[50].Daudt L, Maccario R, Locatelli F, et al. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated,antileukemia human cytotoxic T lymphocyte lines. J Immunother.2008;31(4):385-93.
[51].Komita H, Homma S, Saotome H, et al. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol. 2006; 45 (5):662-72.
[52]. Chen CH, Lee HS, Huang GT, Yang PM, et al.Phenotypic analysis of tumor-infiltrating lymphocytes in hepatocellular carcinoma.Hepatogastroenterology. 2007;54(77):1529-33.
[53]. Koido S, Homma S, Hara E, et al. In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J Transl Med. 2008;6:51.
[54]. Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44 Suppl 19:102-7.
[55]. Wu HC, Wang Q, Yang HI, et al. Aflatoxin Bl exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009;18(3):846-53
[56].Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009:13. [Epub ahead of print]
[57]. Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192-9.
[58].Unitt E, Rushbrook SM, Marshall A, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005;41(4):722-30.
[59]. Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13(3):902-11.
[60]. Sasaki A, Tanaka F, Mimori K, et al. Prognostic value of tumor-infiltrating F0XP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol. 2008;34(2):173-9.
[61].Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006;45(2):246-53.
[62].Cai L, Zhang Z, Zhou L, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008;129(3):428-37.
[63].Maki A, Matsuda M, Asakawa M, et al. Decreased CD3 zeta molecules of T lymphocytes from patients with hepatocellular carcinoma associated with hepatitis C virus. Hepatol Res. 2003;27(4):272-278.
[64]. Weidmann E, Whiteside TL, Giorda R, et al.The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res. 1992;52(21):5913-20.
[65]. Zhang J, Dong B, Liang P,et al. Significance of changes in local immunity in patients with hepatocellular carcinoma after percutaneous microwave coagulation therapy. Chin Med J (Engl). 2002;115(9):1367-71.
[66].Homma S, Komita H, Sagawa Y, et al. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against HLA class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology. 2005;115(4):451-61.
[67]. Koido S, Homma S, Hara E, et al. In vitro generation of cytotoxic andregulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J Transl Med. 2008;6:51.
[68]. Wang XH, QinY, Hu MH, et al. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma(HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 2005; 54(10):971-80.
[69].Li ZS, Yang XW, Chen Z, et al. In vivo tumor co-transfection with superantigen and CD80 induces systemic immunity without tolerance and prolongs survival in mice with hepatocellular carcinoma. Cancer Biol Ther.2004:3(7): 660-6.
[70]. Tatsumi T, Takehara T, Katayama K, et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology. 1997;25(5):1108-14.
1. El-Serag HB: Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 127:S27-S34, 2004
2. Kim WR, Gores GJ, Benson JT, et al: Mortality and Hospital Utilization for Hepatocellular Carcinoma in the United States.Gastroenterology 129:486-493, 2005
3. Jepsen P, Vilstrup H, Tarone RE, et al: Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: Recent trends.International Journal of Cancer 121:1624-1626, 2007
4. Davila JA, Weston A, Smalley W, et al: Utilization of screening for hepatocellular carcinoma in the United States. [see comment]. Journal of Clinical Gastroenterology 41:777-82, 2007
5. Kato N, Ji G, Wang Y, Baba M, et al: Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 42:846-853, 2005
6. Ding S-J, Li Y, Tan Y-X, et al: From Proteomic Analysis to Clinical Significance: Overexpression of Cytokeratin 19 Correlates with Hepatocellular Carcinoma Metastasis. Mol Cell Proteomics 3:73-81, 2004
7. Yokoo H, Kondo T, Okano T, et al: Protein expression associated with early intrahepatic recurrence of hepatocellular carcinoma after curative surgery. Cancer Science 98:665-673, 2007
8. Parfitt JR, Marotta P, Alghamdi M, et al: Recurrent hepatocellular carcinoma after transplantation: Use of a pathological score on explanted livers to predict recurrence. Liver Transplantation 13:543-551, 2007
9. Huo TI, Huang YH, Lin HC, et al: Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. American Journal of Gastroenterology 101:975-982,2006
10. Nanashima A, Sumida Y, Abo T, et al: Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. Journal of Gastroenterology 41:250-256, 2006
11. Toyoda H, Kumada T, Osaki Y, et al: Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clinical Gastroenterology & Hepatology 4:1528-1536, 2006
12. Ren Y, Poon RT-P, Tsui H-T, et al: Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and Prognosis. Clin Cancer Res 9:5996-6001,2003
13. Georgiades CS, Liapi E, Frangakis C, et al: Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. Journal of Vascular & Interventional Radiology 17:1619-24, 2006
14. Minagawa M, Ikai I, Matsuyama Y, et al: Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13, 772 patients in Japan. Annals of Surgery 245:909-22, 2007
15. Kee KM, Wang JH, Lee CM, et al: Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5, 613 cases from a medical center in southern Taiwan. International Journal of Cancer 120:2650-5, 2007
16. Ramacciato G, Mercantini P, Cautero N, et al: Prognostic evaluation of the new American Joint Committee on Cancer/International Union Against Cancer staging system for hepatocellular carcinoma: analysis of 112 cirrhotic patients resected for hepatocellular carcinoma. [see comment]. Annals of Surgical Oncology 12:289-97, 2005
17. Takanishi DM, Jr., Severino R, Wong LL: The Cancer of the Liver Italian Program (CLIP) score: validation of a new prognostic system for hepatocellular carcinoma. Hawaii Medical Journal 66:209-12, 2007
18. Ho M-C, Lin J-J, Chen C-N, et al: A Gene Expression Profile for Vascular Invasion can Predict the Recurrence After Resection of Hepatocellular Carcinoma: a Microarray Approach. Annals of Surgical Oncology 13:1474-1484, 2006
19. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma:Comparison of 7 staging systems in an American cohort.Hepatology 41:707-715, 2005
20. Vanderkerken K, Bouwens L, Van Rooi jen N, et al: The role of Kupf fer cells in the differentiation process of hepatic natural killer cells.Hepatology 22:283-90, 1995
21. McCullough KD, Coleman WB, Smith GJ, et al: Age-dependent induction of hepatic tumor regression by the tissue microenvironment after transplantation of neoplastically transformed rat liver epithelial cells into the liver. Cancer Research 57:1807-13, 1997
22. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47(3): 897-907, 2008
23. Unitt E, Rushbrook SM, Marshall A, et al: Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells, [see comment]. Hepatology 41:722-30, 2005
24. Kanmura S, Uto H, Kusumoto K, et al: Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology 45:948-956, 2007
25. Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. [see comment]. Journal of Clinical Oncology 25:2586-93, 2007
26. Kobayashi N, Hiraoka N, Yamagami W, et al: F0XP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clinical Cancer Research 13:902-11, 2007
27. Cai XY, Gao Q, Qiu SJ, et al: Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. Journal of Cancer Research & Clinical Oncology 132:293-301, 2006
28. Cai XY, Qiu SJ, Wu ZQ, et al: [Relationship between dendritic cells and memory T lymphocytes in tumor site and prognosis of hepatocellular carcinoma]. Chung-Hua i Hsueh TsaChih [Chinese Medical Journal] 85:671-5,2005
29. Hira E, Ono T, Dhar DK, et al: Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103:588-598, 2005
30. Wang L, Wu WZ, Sun HC, et al: Mechanism of Interferon Alpha on Inhibition of Metastasis and Angiogenesis of Hepatocellular Carcinoma After Curative Resection in Nude Mice. Journal of Gastrointestinal Surgery 7:587-594, 2003
31. Mann CD, Neal CP, Garcea G, et al: Prognostic molecular markers in hepatocellular carcinoma: A systematic review. European Journal of Cancer 43:979-992, 2007
32. Poon TCW, Wong N, Lai PBS, et al: A Tumor Progression Model for Hepatocellular Carcinoma: Bioinformatic Analysis of Genomic Data. Gastroenterology 131:1262-1270, 2006
33. Qin LX, Tang ZY, Sham JST, et al: The Association of Chromosome 8p Deletion and Tumor Metastasis in Human Hepatocellular Carcinoma. Cancer Res 59:5662-5665, 1999
34. Kusano N, Okita K, Shirahashi H, : Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer 94:746-751, 2002
35. Chan KL, Lee JM, Guan XY: High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer 94:3179-3185, 2002
36. Li SP, Wang HY, Li JQ, et al: Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. Journal of Hepatology 34:840-849, 2001
37. Pang JZ, Qin LX, Ren N, et al: Loss of Heterozygosity at D8S298 Is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma. Clin Cancer Res 13:7363-7369, 2007
38. Wu L, Xu X, Shen J, et al: MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation. Journal of Surgical Oncology 96:62-68, 2007
39. Chen GG, Ho RLK, Wong J, et al: Single nucleotide polymorphism in the promoter region of human alpha-fetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC). European Journal ofSurgical Oncology (EJSO) 33:882-886, 2007
40. Dharel N, Kato N, Muroyama R, et al: MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C. Clin Cancer Res 12:4867-4871, 2006
41. Luk JM, Lam CT, Siu AF, et al: Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. PROTEOMICS 6:1049-1057, 2006
42. Ren N, Qin LX, Tu H, et al: The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 132:399-407, 2006
43. Wong IHN, Lau WY, Leung T, et al: Hematogenous Dissemination of Hepatocytes and Tumor Cells after Surgical Resection of Hepatocellular Carcinoma: A Quantitative Analysis. Clin Cancer Res 5:4021-4027, 1999
44. Sun HC, Zhang W, Qin LX, et al: Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. Journal of Hepatology 47:684-690, 2007
45. Chau GY WC, et al: Serum Interleukin-10 But Not Interleukin-6 Is Related to Clinical Outcome in Patients With Resectable Hepatocellular Carcinoma. Annals of surgery 231:552-558. , 2000
46. Ikeguchi M HY: Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie 28:255-9. Epub 2005 Apr 29., 2005
47. Okabe H, Satoh S, Kato T, et al: Genome-wide Analysis of Gene Expression in Human Hepatocellular Carcinomas Using cDNA Microarray:Identification of Genes Involved in Viral Carcinogenesis and Tumor Progression. Cancer Res 61:2129-2137, 2001
48. Cheung ST, Chen X, Guan XY, et al: Identify Metastasis-associated Genes in Hepatocellular Carcinoma through Clonality Delineation for Multinodular Tumor. Cancer Res 62:4711-4721, 2002
49. Iizuka N, Oka M, Yamada Okabe H, et al: Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. The Lancet 361:923-929, 2003
50. Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416-423,2003
51. Mas VR, Maluf DG, Stravitz R, et al. : Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: Genes involved in tumor progression. Liver Transplantation 10:607-620, 2004
52. Katoh H, Shibata T, Kokubu A, et al: Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: Identification of genetic indicators to predict patient outcome. Journal of Hepatology 43:863-874, 2005
53. Okamoto M, Utsunomiya T, Wakiyama S, et al: Specific Gene-Expression Profiles of Noncancerous Liver Tissue Predict the Risk for Multicentric Occurrence of Hepatocellular Carcinoma in Hepatitis C Virus - Positive Patients. Annals of Surgical Oncology 13:947-954, 2006
54. Valeria R Mas DGM, Kellie J Archer, Kenneth Yanek, Bridgette Williams, Robert A Fisher: Differentially Expressed Genes between Early and Advanced Hepatocellular Carcinoma (HCC) as a Potential Tool for Selecting Liver Transplant Recipients. Mol Med. Apr-Jun; 12: 97-104. ,2006
55. Lee JS, Heo J, Libbrecht L, et al: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12:410-416, 2006
56. Wang SM, Ooi LLPJ, Hui KM: Identification and Validation of a Novel Gene Signature Associated with the Recurrence of Human Hepatocellular Carcinoma. Clin Cancer Res 13:6275-6283, 2007
57. Hideaki Somura NI, Takao Tamesa, Kazuhiko Sakamoto, Takashi Hamaguchi, Ryouichi Tsunedomi, Hisafumi Yamada-Okabe, Mikiko Sawamura,Masaya Eramoto, Takanobu Miyamoto, Yoshihiko Hamamoto, Masaaki Oka: A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy. Oncology Reports 19:489-95, 2008
58. Melle C, Ernst G, Scheibner O, et al: Identification of Specific Protein Markers in Microdissected Hepatocellular Carcinoma. J. Proteome Res. 6:306-315, 2007
59. Luk JM, Lam BY, Lee NPY, et al: Artificial neural networks and decision tree model analysis of liver cancer proteomes. Biochemical and Biophysical Research Communications 361:68-73, 2007
60. Yi X, Luk JM, Lee NP, et al: Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence. Mol Cell Proteomics 7:315-325, 2008
61. Lim SO PS, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, Yoo BC, Jung GH, Park CK. : Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol 11:2072-2079,2005
62. Poon TCW, Yip TT, Chan ATC, et al: Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its Subtypes. Clin Chem 49:752-760, 2003